DrugPatentWatch Database Preview
RITUXAN Drug Profile
» See Plans and Pricing
Summary for Tradename: RITUXAN
| Patents: | 807 |
| Applicants: | 2 |
| BLAs: | 2 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for RITUXAN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RITUXAN |
Recent Clinical Trials for RITUXAN
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Merck Sharp & Dohme Corp. | Phase 1/Phase 2 |
| Rutgers, The State University of New Jersey | Phase 2 |
| Deepa Jagadeesh | Phase 2 |
Recent Litigation for RITUXAN
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Ravgen, Inc. v. PerkinElmer Inc. | 2020-06-01 |
| Ravgen, Inc. v. Natera, Inc. | 2020-06-01 |
| CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. | 2019-07-12 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Celltrion, Inc. | 2018-05-04 |
| Apotex Inc. | 2018-02-23 |
| 2018-01-08 |
Pharmacology for RITUXAN
| Mechanism of Action | CD20-directed Antibody Interactions |
Patent Text Search: US Patents for RITUXAN
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR) | 2032-09-12 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | Pharmacyclics LLC (Sunnyvale, CA) | 2030-06-03 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | Array BioPharma Inc. (Boulder, CO) | 2028-10-22 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | YALE UNIVERSITY (New Haven, CT) | 2021-05-01 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | VentiRx Pharmaceuticals, Inc. (Seattle, WA) | 2030-04-21 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) | 2034-10-30 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for RITUXAN
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Cyprus | 1110989 | Start Trial |
| Canada | 2720677 | Start Trial |
| Argentina | 064444 | Start Trial |
| European Patent Office | 2618146 | Start Trial |
| Cyprus | 1118918 | Start Trial |
| Israel | 184617 | Start Trial |
| Ecuador | SP088812 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for RITUXAN
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 15C0029 | France | Start Trial | PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023 |
| LUC00044 | Luxembourg | Start Trial | PRODUCT NAME: INOTUZUMAB OZOGAMICINE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BESPONSA ); AUTHORISATION NUMBER AND DATE: EU/1/17/1200 20170703 |
| 1590021-0 | Sweden | Start Trial | PRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/14/945 20141023 |
| 132017000135500 | Italy | Start Trial | PRODUCT NAME: SARILUMAB(KEVZARA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1196, 20170627 |
| CA 2017 00012 | Denmark | Start Trial | PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707 |
| PA2020505 | Lithuania | Start Trial | PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
| 122015000013 | Germany | Start Trial | PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE (IMNOVID); REGISTRATION NO/DATE: EU/1/13/850 20130805 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
